Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Biovail licenses diltiazem for Scandinavian market

Sep. 17, 1997

A-127722.5, a selective, orally active ETA antagonist for restenosis

Sep. 17, 1997

Natrecor in CHF: phase III results

Sep. 16, 1997

Results with PLC Systems' TMR System reported

Sep. 16, 1997

Myocardial and cerebral vasodilating effects of BMS-180448 in animals

Sep. 15, 1997

Benefits of magnesium sulfate investigated in patients with unstable angina

Sep. 15, 1997

SDZ-MRL-953 prevents sepsis in cancer patients

Sep. 15, 1997

Preclinical profile of Ono-1101 published

Sep. 15, 1997

Myocardial protective effects of Hoe-642 evaluated in porcine hearts

Sep. 12, 1997

T Cell Sciences recipient of SBIR grant to develop atherosclerosis model

Sep. 12, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...